First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi

Angela Collarino, Renato A. Valdés Olmos, Peter A. Neijenhuis, Wietske C. Den Hartog, Frederik Smit, Lioe Fee De Geus-Oei, Lenka M. Pereira Arias-Bouda

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
10 Downloads (Pure)

Abstract

OBJECTIVE. The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.

MATERIALS AND METHODS. From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: Stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.

RESULTS. The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50%) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97%). Two hematomas and three vasovagal reactions were observed.

CONCLUSION. Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.

Original languageEnglish
Pages (from-to)1367-1373
Number of pages7
JournalAmerican Journal of Roentgenology
Volume209
Issue number6
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Technetium Tc 99m Sestamibi
Breast
Biopsy
Molecular Imaging
Equipment and Supplies
Needles
Vacuum
Hematoma
Software

Keywords

  • Tc-sestamibi
  • Breast cancer
  • Molecular breast imaging
  • Radioguided biopsy

Cite this

Collarino, A., Valdés Olmos, R. A., Neijenhuis, P. A., Den Hartog, W. C., Smit, F., De Geus-Oei, L. F., & Pereira Arias-Bouda, L. M. (2017). First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi. American Journal of Roentgenology, 209(6), 1367-1373. https://doi.org/10.2214/AJR.17.18083
Collarino, Angela ; Valdés Olmos, Renato A. ; Neijenhuis, Peter A. ; Den Hartog, Wietske C. ; Smit, Frederik ; De Geus-Oei, Lioe Fee ; Pereira Arias-Bouda, Lenka M. / First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi. In: American Journal of Roentgenology. 2017 ; Vol. 209, No. 6. pp. 1367-1373.
@article{1154c489fc5942c8ab155917527d8a76,
title = "First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi",
abstract = "OBJECTIVE. The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.MATERIALS AND METHODS. From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: Stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.RESULTS. The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50{\%}) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97{\%}). Two hematomas and three vasovagal reactions were observed.CONCLUSION. Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.",
keywords = "Tc-sestamibi, Breast cancer, Molecular breast imaging, Radioguided biopsy",
author = "Angela Collarino and {Vald{\'e}s Olmos}, {Renato A.} and Neijenhuis, {Peter A.} and {Den Hartog}, {Wietske C.} and Frederik Smit and {De Geus-Oei}, {Lioe Fee} and {Pereira Arias-Bouda}, {Lenka M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.2214/AJR.17.18083",
language = "English",
volume = "209",
pages = "1367--1373",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

Collarino, A, Valdés Olmos, RA, Neijenhuis, PA, Den Hartog, WC, Smit, F, De Geus-Oei, LF & Pereira Arias-Bouda, LM 2017, 'First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi' American Journal of Roentgenology, vol. 209, no. 6, pp. 1367-1373. https://doi.org/10.2214/AJR.17.18083

First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi. / Collarino, Angela; Valdés Olmos, Renato A.; Neijenhuis, Peter A.; Den Hartog, Wietske C.; Smit, Frederik; De Geus-Oei, Lioe Fee; Pereira Arias-Bouda, Lenka M.

In: American Journal of Roentgenology, Vol. 209, No. 6, 01.12.2017, p. 1367-1373.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi

AU - Collarino, Angela

AU - Valdés Olmos, Renato A.

AU - Neijenhuis, Peter A.

AU - Den Hartog, Wietske C.

AU - Smit, Frederik

AU - De Geus-Oei, Lioe Fee

AU - Pereira Arias-Bouda, Lenka M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - OBJECTIVE. The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.MATERIALS AND METHODS. From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: Stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.RESULTS. The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50%) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97%). Two hematomas and three vasovagal reactions were observed.CONCLUSION. Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.

AB - OBJECTIVE. The purpose of this study is to evaluate a new device using molecular breast imaging (MBI) for 99mTc-sestamibi-guided stereotactic lesion localization as a complementary biopsy tool.MATERIALS AND METHODS. From December 2012 to May 2016, a total of 38 consecutive women (mean age, 59 years; range, 41-77 years) underwent 99mTc-sestamibi-guided biopsy using a new MBI-based device and were retrospectively reviewed. The biopsy modality used five steps: Stereotactic localization of the 99mTc-sestamibi-avid lesion, calculation of coordinates of the lesion location using dedicated software, placement of the needle, verification of the correct needle position, and tissue sampling with a vacuum-assisted device followed by placement of a radiologic marker at the biopsy site and ex vivo measurement of the biopsy specimens.RESULTS. The procedure was technically successful in all 38 lesions. In all cases, biopsy samples were radioactive and adequate for histopathologic analysis. Nineteen lesions (50%) were found to be malignant, and the remaining lesions were found to be benign. The mean procedure time was 71 minutes (range, 44-112 minutes). The radiologic marker was successfully deployed in 37 lesions (97%). Two hematomas and three vasovagal reactions were observed.CONCLUSION. Technetium-99m sestamibi-guided biopsy performed using a dedicated MBI-based device is technically feasible and represents a valuable complementary biopsy tool in breast lesion diagnosis.

KW - Tc-sestamibi

KW - Breast cancer

KW - Molecular breast imaging

KW - Radioguided biopsy

UR - http://www.scopus.com/inward/record.url?scp=85035191377&partnerID=8YFLogxK

U2 - 10.2214/AJR.17.18083

DO - 10.2214/AJR.17.18083

M3 - Article

VL - 209

SP - 1367

EP - 1373

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 6

ER -